The ability of tumors to degrade glucose, even in the presence of oxygen, through the anaerobic transketolase-dependant pentose phosphate pathway has recently shown TKTL1 to particularly influence total transketolase activity and cell proliferation [1
]. TKTL1 mRNA silencing (via small interfering anti-TKTL1-mRNA constructs) leads to inhibition of cell proliferation in colorectal cancer; protein overexpression and a significant correlation to Her2 overexpression was found in breast cancer cells where 89% expressed TKTL1 and 45% showed strong expression [2
]. Gastric tumors and granulosa cell tumors of the ovary were also found to express high amounts of TKTL1 (36.9%; 81%) [4
]. Further, with renal cancer another carcinoma displayed intensively elevated transketolase activity due to TKTL1-upregulation [6
]. Proliferation-influencing activities of TKTL1 might play a role in a variety of cancers. Hence we investigated a capacious collective of 88 formalin-fixed non-small cell lung cancer (NSCLC)-tissues (39 adenocarcinomas; 49 squamous cell carcinomas) by immunohistochemistry to describe TKTL1 protein expression in human lung carcinomas. A collective of 24 breast cancer specimens was also included in the study (21 invasive-ductal; 1 tubular; 1 lobular; 1 mucinous carcinoma). Further, we challenged a potential correlation of TKTL1 to age, sex, TNM-classification and grading as well as TTF1 and SPA expression.
After lobectomy or pneumonectomy tumor tissues were immediately fixed with formalin and processed in the following over-night-procedure: formalin 1 h 30 min; following an alcohol series (70% 1 h 30 min; 80% 1 h; 96% 1 h for 2 times; 100% 1 h for 3 times; Histoclear for 1 h 2 times; subsequently paraplast is brought into the tissue at 60°C for 1 h 30 min; then another 2 h). Each step was followed by a 30 min. drop-off delay before the next step was started. After resection breast cancer specimens were processed in the same manner. Additionally we investigated 40 HOPE (Hepes Glutamic Acid Buffer Mediated Organic Solvent Protection Effect)-fixed NSCLC-tissue probes to validate the formalin fixation. After embedding in paraffin the blocks were shelved for 0–6 years within a tissue archive. For increased inter specimen comparability and even staining quality we utilized Tissue Microarrays (TMAs). These TMAs were produced from donor tissue blocks using an MTA1 (Manual Tissue Arrayer 1) device (Alphametrix, Germany), cut and mounted on microscope slides (Super Frost Plus, Langenbrink, Germany). For homogeneous high-throughput staining conditions the tissues were stained automatically (Autostainer 480, Medac, Germany).
The TMAs were deparaffinized and rehydrated by the following series at room temperature: 10 min. xylol incubation; 2 min. absolute alcohol (2 times); 2 min. 96% alcohol (2 times); 2 min. 90% alcohol; 2 min. 80% alcohol; 2 min. 70% alcohol; 2 min. aqua dest. (2 times). For antigen retrieval 30 min. citrate buffer cooking in was chosen. The primary antibody (anti-TKTL1; clone: JFC12T10; Zytomed Systems, Berlin) was incubated for 30 min. in a 1:100 dilution. We used an enzyme-polymersystem (ZytochemPlus HRP Polymer Kit, Zytomed Systems) for sensitive detection with permanent AEC (Zytomed Systems) as chromogen. Tissue arrays were counterstained by incubation in Mayer's haemalum for 5 minutes. Negative-controls were included in each staining series under omission of primary antibody.
The immunohistochemical stainings displayed elevated expression of TKTL1 in human lung cancer: 40.9% expressed TKTL1 weakly (score 1), 38.6% moderately (score 2), 17.1% strongly (score 3), and 3.4% of the tumors were TKTL1-negative (score 0; Figure ). Breast cancer specimen stainings were scored 0: none; scored 1: 32%; scored 2: 36%; scored 3: 32% (Figure ). In general, adenocarcinomas were more often strongly positive (score 3) than the squamous cell carcinomas (22.1% for adenocarcinomas and 12.2% for squamous cell carcinomas). Staining of the HOPE-fixed specimens showed comparable results; these results verify findings in the five cases of adenocarcinomas of the lung described by Langbein et al. [7
Allocation of the stained lung cancer specimens to the four different staining scores.
Allocation of the stained breast cancer specimens to the four staining scores.
Signals were recognized in the cytoplasm and occasionally in nuclei of tumor cells. There was a conspicuous amount of signal-containing alveolar macrophages and alveolar epithelial cells type II (AEC II cells), observed in the close neighborhood of the NSCLC (Figures and ) as well as in completely healthy parts of lung tissue (not shown). Examples of stained tumor types, alveolar macrophages and AEC II cells are shown in figure . No staining was found in negative controls. Comparison of TKTL1-expression to several clinical parameters revealed that there is no significant correlation between TKTL1-appearance and age, sex, TNM-classification parameters or tumor grading. Further no correlation could be defined concerning SPA and TTF1 expression.
Figure 3 Examples of TKTL1-stained A) adenocarcinomas; B) squamous cell carcinomas; C) breast cancer specimens; D) TKTL1-positive macrophages in the neighbourhood of an adenocarcinoma and E) TKTL1-positive AEC II cells in the neighbourhood of an adenocarcinoma (more ...)
A high variability of TKTL1-expression has been described in several tumor types. There is proven evidence that TKTL1-associated or -inducing, abnormal glucose degradation is increased in tumors [3
]. But TKTL1 is also a key enzyme in the healthy organism whose activation-status influences the balance of anaerobic glucose- or oxygen-focussed bioenergy-obtainment. Natural appearance is proven through positive detected macrophages and AEC II cells (Figures and ) as well as signals in healthy lung tissues. Therefore tests on cancer cells or cancer tissues alone are not capable to gain insights into the complex situation in patients subjected to diets or other treatments. We have shown that a large portion of NSCLC overexpresses TKTL1; moreover there was a significant expression in non malignant cells of the lungs. Although it is tempting to speculate of a potential therapeutic benefit by modulation of TKTL1-activity in the future, further studies are necessary to investigate the real amount of effects during TKTL1-targeted diets or therapies within the human organism.